Research progress on combined strategies for functional cure of HBV

doi:10.3877/cma.j.issn.1674-0785.2025.03.011

Abstract

Abstract:

Chronic hepatitis B virus （HBV） infection is a significant global public health issue，severely impacting patients' quality of life and increasing the risk of liver cirrhosis and hepatocellular carcinoma.In recent years，functional cure has emerged as a major research priority，particularly with the combined application of small interfering RNA （siRNA） technology and Toll-like receptor 8 （TLR8） agonists.This article reviews the latest advancements in the field of functional cure for HBV infection，with a focus on analyzing the synergistic mechanisms between siRNAs （e.g.，VIR-2218） and TLR8 agonists.Through an indepth examination of the existing literature，this paper outlines the potential advantages and prospects of these two therapeutic strategies in HBV clearance，especially their interplay in enhancing immune responses and promoting viral eradication，with an aim to provide an important theoretical foundation for subsequent clinical research.

Key words: Chronic hepatitis B virus, Functional cure, siRNA, VIR-2218, TLR8 agonist, Synergistic mechanism

Sachula Bao, Dusu Wen. Research progress on combined strategies for functional cure of HBV[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(03): 234-239.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2025.03.011

https://zhlcyszz.cma-cmc.com.cn/EN/Y2025/V19/I03/234

References 45

1	Cao W，Xie S，Zhang L，et al.Expression of functional molecule on plasmacytoid dendritic cells is associated with HBsAg loss in HBeAgpositive patients during PEG-IFN α-2a treatment ［J］.Front Immunol，2022，13： 891424.
2	Gao N，Guan G，Xu G，et al.Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy ［J］.Aliment Pharmacol Ther，2023，58（10）： 1086-1098.
3	Zhang M，Chen H，Liu H，et al.The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy ［J］.Biomark Res，2024，12（1）：84.
4	Zheng JR，Wang ZL，Feng B.Hepatitis B functional cure and immune response ［J］.Front Immunol，2022，13：1075916.
5	Cao W，Lu H，Zhang L，et al.Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy ［J］.Front Immunol，2022，13： 1067362.
6	Mohtashemi N，Dubé K，Thio C，et al.Patient acceptability of，and attitudes towards，hepatitis B cure research - A scoping review and identification of knowledge gaps ［J］.J Virus Erad，2023，9（4）： 100354.
7	Martinez MG，Villeret F，Testoni B，et al.Can we cure hepatitis B virus with novel direct-acting antivirals？［J］.Liver Int，2020，1： 27-34.
8	Boyd A，Dezanet LNC，Lacombe K.Functional cure of hepatitis B virus infection in individuals with HIV-coinfection： A literature review［J］.Viruses，2021，13（7）： 1341.
9	Xu R，Hu P，Li Y，et al.Advances in HBV infection and replication systems in vitro ［J］.Virol J，2021，18（1）： 105.
10	Li Y，Li S，Duan X，et al.Macrophage phenotypes and hepatitis B virus infection ［J］.J Clin Transl Hepatol，2020，8（4）： 424-431.
11	Duchemin NJ，Loonawat R，Yeakle K，et al.Hypoxia-inducible factor affects hepatitis B virus transcripts and genome levels as well as the expression and subcellular location of the hepatitis B virus core protein［J］.Virology，2023，586： 76-90.
12	Jiang B，Zhang Y，Li G，et al.Research progress on immune evasion of mycoplasma hyopneumoniae ［J］.Microorganisms，2024，12（7）： 1439.
13	Yee Mon KJ，Blander JM.TAP-ing into the cross-presentation secrets of dendritic cells ［J］.Curr Opin Immunol，2023，83： 102327.
14	Deng H，Gao H，Liu Y，et al.Comparative analysis of HBV basic core promoter/pre-core gene mutations and viral quasispecies diversity in HIV/HBV co-infected and HBV mono-infected patients ［J］.Acta Virol，2022，66（1）： 18-26.
15	Stone D，Long KR，Loprieno MA，et al.CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice ［J］.Mol Ther Methods Clin Dev，2020，20： 258-275.
16	Hayashi S，Isogawa M，Kawashima K，et al.Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application ［J］.Sci Rep，2022，12（1）： 2133.
17	Hong X，Hu J.Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover ［J］.J Med Virol，2020，92（8）：935-937.
18	Duan Z，Dong J，Liu Y，et al.Awareness of HBV functional cure and attitude toward related clinical trials among patients with chronic hepatitis B in China ［J］.Patient Prefer Adherence，2023，17： 2063-2072.
19	Sun H，Li Y，Zhang P，et al.Targeting toll-like receptor 7/8 for immunotherapy： recent advances and prospectives ［J］.Biomark Res，2022，10（1）： 89.
20	Ayithan N，Tang L，Tan SK，et al.Follicular helper T （T＜sub＞FH＜/sub＞） cell targeting by TLR8 signaling for improving HBsAg-specific B cell response in chronic hepatitis B patients ［J］.Front Immunol，2021，12： 735913.
21	Roca Suarez AA，Plissonnier ml，Grand X，et al.TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism ［J］.Gut，2024，73（12）： 2012-2022.
22	Weickert TW，Ji E，Galletly C，et al.Toll-Like receptor mRNA levels in schizophrenia： association with complement factors and cingulate gyrus cortical thinning ［J］.Schizophr Bull，2024，50（2）： 403-417.
23	Qiu J，Zou Y，Li S，et al.Discovery of benzimidazole substituted 1，2，4-oxadiazole compounds as novel anti-HBV agents with TLR8-agonistic activities ［J］.Eur J Med Chem，2022，244： 114833.
24	Abdolmohammadi-Vahid S，Baradaran B，Sadeghi A，et al.Effects of toll-like receptor agonists and SARS-CoV-2 antigens on interferon（IFN） expression by peripheral blood CD3+ T cells from COVID-19 patients ［J］.Exp Mol Pathol，2024，137： 104897.
25	Gane EJ，Dunbar PR，Brooks AE，et al.Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression ［J］.J Hepatol，2023，78（3）： 513-523.
26	Wang T，Kuley R，Hermanson P，et al.Immune complexes-mediated activation of neutrophils in systemic lupus erythematosus is dependent on RNA recognition by toll-like receptor 8 ［J］.Front Immunol，2024，15： 1515469.
27	Rawal P，Siddiqui H，Hassan M，et al.Endothelial cell-derived TGF-β Promotes epithelial-mesenchymal transition via CD133 in HBxonfected hepatoma cells ［J］.Front Oncol，2019，9： 308.
28	Moini M，Fung S.HBsAg loss as a treatment endpoint for chronic HBV infection： HBV cure ［J］.Viruses，2022，14（4）： 657.
29	Wooddell CI，Sanders D，Xu Z，et al.Characterization of hepatitis B virus transcripts in chronically HBV-infected chimpanzees and patients treated with ARC-520 siRNA demonstrates transcriptional silencing of cccDNA ［J］.Viruses，2024，16（12）： 1943.
30	Yao Q，Peng B，Li C，et al.SLF2 Interacts with the SMC5/6 complex to direct hepatitis B virus episomal DNA to promyelocytic leukemia bodies for transcriptional repression ［J］.J Virol，2023，97（7）：e0032823.
31	Hu K，Zai W，Xu M，et al.Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-α and small-interfering RNA synergy ［J］.mBio，2024，15（12）： e0241524.
32	Gupta SV，Fanget MC，MacLauchlin C，et al.Clinical and preclinical single-dose pharmacokinetics of VIR-2218，an RNAi therapeutic targeting HBV infection ［J］.Drugs R D，2021，21（4）： 455-465.
33	Yuen MF，Lim YS，Yoon KT，et al.VIR-2218 （elebsiran） plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection： a phase 2 study ［J］.Lancet Gastroenterol Hepatol，2024，9（12）： 1121-1132.
34	Gane E，Lim YS，Kim JB，et al.Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B： Results from randomized clinical trials ［J］.J Hepatol，2023，79（4）： 924-932.
35	Gupta AK，Taylor D，Nouri K.Lasers for treatment of androgenetic alopecia： an in-depth analysis ［J］.Lasers Med Sci，2025，40（1）： 108.
36	Janczura J，Brzdęk M，Dobrowolska K，et al.Steatotic liver disease in patients treated for chronic hepatitis B ［J］.Pol Arch Intern Med，2025，135（3）： 16942.
37	张思慧，崔富强.对慢性HBV 感染者全部治疗策略的卫生经济学考量［J］.中华肝脏病杂志，2024，32（5）： 406-410.
38	张敏，李静，王福生.儿童慢性乙型肝炎抗病毒治疗与临床治愈：进展与挑战［J］.中华肝脏病杂志，2021，29（12）： 1218-1223.
39	Han J，Guo Y，Zhang X，et al.Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos（t）ide analogs ［J］.Turk J Gastroenterol，2023，34（1）： 53-61.
40	艾小委，张梦阳，孙亚朦，等.从全球视角看慢性乙型肝炎扩大治疗新理念［J］.中华肝脏病杂志 2024，32（5）： 385-388.
41	汪梦兰，陈恩强.依从性影响慢性乙型肝炎的治疗［J］.中华肝脏病杂志，2022，30（11）： 1266-1269.
42	Huang CC，Wu KL，Liu JS，et al.Autonomic impairment in treatmentnaive patients with chronic hepatitis B and C infections［J］.Auton Neurosci，2022，238： 102928.
43	Liang H，Zheng X，Mao Q，et al.Comparative efficacy and safety of pegylated interferon-alpha monotherapy vs combination therapies with entecavir or tenofovir in chronic hepatitis B patients ［J］.Microbiol Spectr，2025，e0269424.
44	Wu JF，Tai CS，Chang KC，et al.Predictors of functional cure of chronic hepatitis B virus infection： A long-term follow-up study ［J］.Clin Gastroenterol Hepatol，2025，23（4）： 583-590.e3.
45	Gu F，Zeng K，Lan X，et al.Measuring HBV pregenomic RNA may be a potential biomarker to determine HBV functional cure in HIV/HBVco-infected patients with HBsAg loss ［J］.J Med Virol，2024，96（6）：e29762.

[1]	Wenbin Cai, Wei Lyu, Yunyou Duan, Jia Wang. In vitro effect of nanobubbles carrying siRNA combined with ultrasound targeted destruction on glioma cell proliferation [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2018, 15(12): 960-966.
[2]	An-ding LIU, Xue-jun DONG, Ming-feng YANG, Zhuan ZHENG, Jian-jun CHEN. Effect of hTERT gene silencing by RNA interference on proliferation and apoptosis of human breast cancer cells [J]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(05): 22-26.
[3]	Jun-min WEI, Ming HOU, Li-zhen LI, Peng GAO. Reversal of multidrug resistance of human breast cancer MCF-7/ADR cells by small interfering RNAs combined with antisense oligodeoxyribonucleotides for inhibition of MDR1 gene expression [J]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(04): 436-442.
[4]	Hai-xia GUO, Hong-man XUE, Yang LI, Zhe MENG, Huan CHEN, Wen-yi LI. Design of human vascular endothelial growth factor receptor 2 siRNA and construction of its expression vector [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2007, 03(03): 129-129.
[5]	Ying Duan, Xiaomei Wang, Yingying Zhao, Ben Li, Min Quan, Weini Ou, Huichun Xing. Prevalence and influencing factors of chronic hepatitis B virus infection complicated with chronic kidney disease [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(05): 422-426.
[6]	Dong-lin ZENG, Hong-zhang HUANG, Lei-tao ZHANG. Negative regulation of matrix metalloproteinases-2 gene expression to inhibit the invasiveness of ameloblastoma cells [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2008, 02(01): 26-31.
[7]	Yiqin Wang, Shun Li, Xiaofang Zeng, Zhili Ma, Lixia Xu, Ming Kuang. Expression and function of circRNA circEIF6 in hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(04): 252-257.
[8]	Zhibo Gu, lin Hao, Ming Lu, Jiangang Chen. Photodynamic nanocarriers combined with siP3H4 for precise targeting therapy in the treatment of bladder cancer: a pilot study [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 633-641.
[9]	Jianbo Ma, Kai Sun, Chong Ma, Lei Cao, Jianping Zhao, Lukui Chen. Silencing GLI1 by siRNA inhibits the proliferation of glioma U87 cells [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2015, 01(05): 30-32.

Please choose a citation manager

Content to export